OSSIO Secures $50 Million Credit Facility To Fund Global Growth

The financing will support the expansion of OSSIO's orthopedic fixation technology worldwide.

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

OSSIO, a medical technology company focused on developing a potential alternative to metal implants, has closed a $50 million credit facility with Horizon Technology Finance Corporation and Monroe Capital. The financing will provide growth capital as OSSIO expands its OSSIOfiber Intelligent Bone Regeneration Technology globally.

Why it matters

This investment reflects the growing demand for innovative orthopedic solutions that can improve patient outcomes and experiences. OSSIO's metal-free technology aims to disrupt the traditional orthopedic fixation market, which has historically relied on metal implants.

The details

The $50 million credit facility includes an initial $40 million senior credit facility, with an additional $10 million available to support future growth. OSSIO plans to use the financing to accelerate the global expansion of its orthopedic fixation technology, which is designed to be a potential alternative to metal implants. The company conducts product development and manufacturing in Caesarea, Israel, and maintains commercial operations in Palmetto, Florida.

  • OSSIO closed the $50 million credit facility on February 13, 2026.

The players

OSSIO

A medical technology company focused on developing a potential alternative to metal implants in the global orthopedic fixation market through its OSSIOfiber Intelligent Bone Regeneration Technology.

Horizon Technology Finance Corporation

A specialty finance company that provides secured loans to venture-backed companies in the technology, life sciences, healthcare, and sustainability industries.

Monroe Capital

A private credit asset management firm that provides senior and junior debt and equity co-investments to middle-market companies in the U.S. and Canada.

Brian Verrier

Chief Executive Officer of OSSIO.

Paul Seitz

Chief Investment Officer of Horizon Technology Finance.

Mark Solovy

Managing Director and Co-Head of the Technology Finance Group at Monroe Capital.

Got photos? Submit your photos here. ›

What they’re saying

“We are thrilled to partner with Horizon Technology Finance and Monroe Capital on this growth capital investment. We look forward to executing on our strategy to expand our orthopedic fixation technology globally. This partnership combines deep healthcare technology expertise with growth capital. Financing from the Horizon and Monroe platform provides the resources needed to accelerate expansion while preserving the company's mission of transforming the orthopedic experience for patients.”

— Brian Verrier, Chief Executive Officer, OSSIO (pulse2.com)

“We are excited to partner with Brian and the OSSIO team as they broaden their global impact in orthopedic medical technology. This investment reflects Horizon's commitment to supporting innovative, venture growth companies through strategic financing. OSSIO marks another Horizon investment within the Israeli technology ecosystem.”

— Paul Seitz, Chief Investment Officer, Horizon Technology Finance (pulse2.com)

“Monroe continues to see exceptional innovation emerging from the Israeli life sciences sector, and OSSIO stands out as a leading force in orthopedic and regenerative technology. Its disruptive, metal-free bone regeneration solutions align directly with our technology finance vertical, and we are proud to support Brian and his team as they globally scale OSSIO's impact.”

— Mark Solovy, Managing Director And Co-Head, Technology Finance Group, Monroe Capital (pulse2.com)

What’s next

OSSIO plans to use the $50 million credit facility to accelerate the global expansion of its OSSIOfiber Intelligent Bone Regeneration Technology, which aims to provide a potential alternative to traditional metal implants in the orthopedic fixation market.

The takeaway

This investment in OSSIO's innovative orthopedic technology highlights the growing demand for disruptive solutions that can improve patient outcomes and experiences in the medical device industry. The partnership between OSSIO, Horizon Technology Finance, and Monroe Capital demonstrates the value of strategic financing to support the global growth of promising healthcare technology companies.